Cargando…
Novel biomarkers identifying hypertrophic cardiomyopathy and its obstructive variant based on targeted amino acid metabolomics
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is an underdiagnosed genetic heart disease worldwide. The management and prognosis of obstructive HCM (HOCM) and non-obstructive HCM (HNCM) are quite different, but it also remains challenging to discriminate these two subtypes. HCM is characterized by d...
Autores principales: | Guo, Lanyan, Wang, Bo, Zhang, Fuyang, Gao, Chao, Hu, Guangyu, Zhou, Mengyao, Wang, Rutao, Zhao, Hang, Yan, Wenjun, Zhang, Ling, Ma, Zhiling, Yang, Weiping, Guo, Xiong, Huang, Chong, Cui, Zhe, Sun, Fangfang, Song, Dandan, Liu, Liwen, Tao, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746752/ https://www.ncbi.nlm.nih.gov/pubmed/36156511 http://dx.doi.org/10.1097/CM9.0000000000002279 |
Ejemplares similares
-
Derivation and Validation of a Screening Model for Hypertrophic Cardiomyopathy Based on Electrocardiogram Features
por: Guo, Lanyan, et al.
Publicado: (2022) -
Identifying Obstructive Hypertrophic Cardiomyopathy from Nonobstructive Hypertrophic Cardiomyopathy: Development and Validation of a Model Based on Electrocardiogram Features
por: Guo, Lanyan, et al.
Publicado: (2023) -
Characterization of the circulating transcriptome expression profile and identification of novel miRNA biomarkers in hypertrophic cardiomyopathy
por: Guo, Lanyan, et al.
Publicado: (2023) -
Excessive branched-chain amino acid accumulation restricts mesenchymal stem cell-based therapy efficacy in myocardial infarction
por: Zhang, Fuyang, et al.
Publicado: (2022) -
Distinct Metabolomic Signatures in Preclinical and Obstructive Hypertrophic Cardiomyopathy
por: Schuldt, Maike, et al.
Publicado: (2021)